FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 354:640-644 February 9, 2006 Number 6 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Hortobagyi, G. N. Related Article by Piccart-Gebhart, M. J. Related Article by Romond, E. H. PubMed Citation

To the Editor: With regard to the reports by Piccart-Gebhart and colleagues and Romond and colleagues (Oct. 20 issue)^1,2 on adjuvant trastuzumab, I have two concerns. The first is that statistics based on immature data are not necessarily significant. As an example, I cite the landmark 1976 report by Bonadonna and colleagues,³ which established adjuvant chemotherapy with cyclophosphamide, methotrexate, and fluorouracil (CMF) for node-positive breast cancer. They reported an extraordinary benefit in progression-free survival among postmenopausal patients at 27 months (P=0.001). However, at 36 months,⁴ there was less benefit (P=0.16), and at 20 years,⁵ there was no survival benefit from . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.